Eteplirsen
Brand name: Exondys-51
Rank #488 of 500 drugs by total cost
$14.4M
Total Cost
192
Total Claims
$14.4M
Total Cost
8
Prescribers
$75K
Cost per Claim
0
Beneficiaries
192
30-Day Fills
$1.8M
Avg Cost/Provider
24
Avg Claims/Provider
About Eteplirsen
Eteplirsen (sold as Exondys-51) was prescribed 192 times by 8 Medicare Part D providers in 2023, costing the program $14.4M. At $75K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 485 | Dihydroergotamine Mesylate (Dihydroergotamine Mesylate) | $14.4M | 6,855 |
| 486 | Clotrimazole/Betamethasone Dip (Clotrimazole-Betamethasone) | $14.4M | 503,015 |
| 487 | Verapamil Hcl (Verapamil Er) | $14.4M | 329,950 |
| 488 | Eteplirsen (Exondys-51) | $14.4M | 192 |
| 489 | Colesevelam Hcl (Colesevelam Hcl) | $14.3M | 50,268 |
| 490 | Bexarotene (Bexarotene) | $14.2M | 1,613 |
| 491 | Ozanimod Hydrochloride (Zeposia) | $14.2M | 1,535 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology